NATCO Pharma (NSE:NATCOPHARM, BOM:524816) received a GST demand order of 2.1 million rupees, along with interest of 1.7 million rupees and a 2.1 million Indian rupees penalty, following an audit covering April 2020 to December 2024.
The demand relates to an alleged shortfall in the amount reported under the reverse charge mechanism in GSTR-3B, according to a Tuesday stock exchange filing. The company said it is evaluating the order and will take appropriate action, adding that it does not expect any material impact on its financial or operational performance.
Shares of the company fell nearly 1% in recent trade.